Notwithstanding the intense interest in systemic cytotoxic therapy in recent years, the great majority of psoriatics are likely to go on needing topical therapy with tar, dithranol or corticosteroids, and a welcome trend is the spreading of interest in day care centres such as those in Paris (Grupper), Stockholm (Thyresson), Stanford (Farber) and San Francisco (Cram) evolving from the out-patient regimes advocated by Ingram in Leeds a generation ago.